BIO-Europe Spring® 2016: Agalimmune brings novel immune-oncology therapy from US to UK
Damian Marron, CEO of Agalimmune Ltd., speaks to Mike Ward, global director of content for Informa Pharma Intelligence's insights portfolio, about the company's novel immuno-oncology technology and how it might fit into the market further down the line. Agalimmune is focused on the development of treatments for patients with solid tumors. The company's lead compound, AGI-134, is a fully-synthetic alpha-Gal glycolipid immunotherapy that recruits a patient's immune system to target autologous tumor antigens, to attack the patient's own tumor cells. The company is based in the UK but it also has a lab in Massachusetts, US, where the technology originates from.